This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Tyrosine kinases recruited to a receptor following hormone binding are receptor-associated tyrosine kinases and are involved in a number of signaling cascades, in particular those involved in cytokine signaling (but also others, including growth hormone). One such receptor-associated tyrosine kinase is Janus kinase (JAK), many of whose effects are mediated by STAT proteins. (See JAK-STAT pathway.)
== Related compounds == The naphthoquinones lawsone methyl ether and methylene-3,3'-bilawsone are some of the active compounds in Impatiens balsamina leaves. Juglone is a structural isomer used as a brown dye. Atovaquone is a synthetic antimicrobial agent that can be manufactured from lawsone.
Lyon, Davor Solter and Azim Surani, for their pioneering work on epigenetic gene regulation in mammalian embryos 2005 Martin Chalfie and Roger Y. Tsien, for their pioneering development of powerful new tools that allow the direct visualization of molecules in living cells 2004 Andrew Z. Fire, Craig C. Mello, Victor Ambros and Gary Ruvkun, for their pioneering achievements in the discovery of gene silencing by double-stranded RNA 2003 Masakazu Konishi, Peter Marler and Fernando Nottebohm, for their pioneering achievements in the ethology and neurology of birdsong 2002 Ira Herskowitz, for his pioneering achievements in yeast genetics and cell biology 2001 Joan A. Steitz, for her work in establishing a sub-field of molecular biology concerning small nuclear ribonucleoproteins 2000 Peter B. Moore, Harry F. Noller, Jr. and Thomas A. Steitz, for their discovery that peptide bond formation on the ribosome is catalyzed exclusively by ribosomal RNA 1999 Roderick MacKinnon, for his research into the molecular foundations of electrical signal generation in neurons and other types of cells 1998 Elizabeth Blackburn and Carol Greider, for their outstanding work on the maintenance of telomeres 1997 H. Robert Horvitz and John E. Sulston, for their pioneering studies of cell lineage in the nematode worm 1996 Richard Axel, Linda B. Buck and A. James Hudspeth, for establishing the molecular basis of the senses of smell and hearing 1995 Thomas D. Pollard and James A. Spudich, for their fundamental contributions to our understanding of molecular motors 1994 Robert G.
Biomedical Chromatography is a monthly peer-reviewed scientific journal, published since 1986 by John Wiley & Sons. It covers research on the applications of chromatography and allied techniques in the biological and medical sciences. The editor-in-chief is Michael Bartlett (University of Georgia).
=== Scientific analyses === Cultural considerations can sometimes interfere with the conservation of human remains, particularly when it comes to physical and chemical analyses, which play an important role in their care. Testing conducted on human remains, especially ancient ones, can include DNA testing, isotope analyses, and carbon-14 dating. The benefits of such testing is sometimes outweighed by the cultural or sacred importance of the remains as well as the risk of damaging them too greatly. According to the Deutscher Museumsbund, there are only three circumstances in which scientific research should be conducted on human remains:
Sources: en.wikipedia.org
== Pathology == Abnormally elevated levels of glucagon may be caused by pancreatic tumors, such as glucagonoma, symptoms of which include necrolytic migratory erythema, reduced amino acids, and hyperglycemia. It may occur alone or in the context of multiple endocrine neoplasia type 1. Elevated glucagon is the main contributor to hyperglycemic ketoacidosis in undiagnosed or poorly treated type 1 diabetes. As the beta cells cease to function, insulin and pancreatic GABA are no longer present to suppress the freerunning output of glucagon. As a result, glucagon is released from the alpha cells at a maximum, causing a rapid breakdown of glycogen to glucose and fast ketogenesis. It was found that a subset of adults with type 1 diabetes took 8 hours longer on average (18 hours vs 10 hours) to approach ketoacidosis when given somatostatin (inhibits glucagon production) with no insulin. Inhibiting glucagon has been a popular idea of diabetes treatment, however, some have warned that doing so will give rise to brittle diabetes in patients with adequately stable blood glucose. The absence of alpha cells (and hence glucagon) is thought to be one of the main influences in the extreme volatility of blood glucose in the setting of a total pancreatectomy.
Further development yielded β-lactamase-resistant penicillins, including flucloxacillin, dicloxacillin, and methicillin. These were significant for their activity against β-lactamase-producing bacterial species, but were ineffective against the MRSA strains. Another development of the line of penicillins was the antipseudomonal penicillins, such as carbenicillin, ticarcillin, and piperacillin, useful for their activity against Gram-negative bacteria. The usefulness of the β-lactam ring was such that related antibiotics, including the mecillinams, the carbapenems and, most important, the cephalosporins, still retain it at the centre of their structures.
Lowering transaction costs in commercial markets: Digital payments, whether integrated in e-commerce platforms or in mobile money accounts, e-wallets, etc., reduce transactions costs within agricultural markets. The need for safe, rapid monetary transactions is particularly apparent in rural areas. Plus, digital payments can provide a gateway to bank accounts, insurance, and credit. Using distributed ledger technologies or smart contracts is another way to reduce trust-related transaction costs in commercial markets. Many retail and food companies have partnered with IBM to develop blockchain pilots related to food safety and traceability, and Alibaba is testing blockchain to reduce fraud in agri-food e-commerce between China and Australia/New Zealand. Lowering transaction costs in government services: Digital payments can also streamline government delivery of agricultural subsidies. In 2011, the Nigerian Federal Ministry of Agriculture and Rural Development started delivering fertilizer subsidy vouchers to e-wallets on mobile phones; by 2013, they had reached 4.3 million smallholders nationwide. Compared to the previous program, the e-vouchers cut costs: from 2011 to 2013, the cost per smallholder farmer receiving fertilizer went from US$225–300 to US$22. The e-vouchers also reached more smallholders, increasing from between 600,000-800,000 in 2011 to 4.3 million in 2013.
== Comparative evolutionary studies == Comparative genomic analyses of the Notch receptor family across mammals have begun to reveal how evolutionary conservation and lineage-specific variation contribute to receptor function and disease susceptibility. Large-scale studies of NOTCH3 across more than 100 mammalian species have identified a high degree of structural conservation, particularly within the extracellular EGF-like repeats that are critical for ligand binding and receptor stability. These analyses have also uncovered rare, naturally occurring species-specific variations, including alterations in conserved cysteine residues and regulatory regions, that appear to be tolerated in some mammals but are pathogenic in humans. Such findings suggest that evolutionary divergence within Notch receptors can illuminate structural constraints and functional thresholds that are not easily detected in single-species studies. Experimental introduction of naturally occurring mammalian variants into model systems has been proposed as a strategy to test bioinformatic predictions and to better understand how subtle changes in Notch receptor structure influence signaling, development, and disease.
In her ruling, she cited Jacobson v Massachusetts, a 1905 U.S. Supreme Court case that upheld the authority of U.S. states to compel people to get vaccinations. On March 25, 2020, Pritzker announced the extension of Illinois's tax filing deadline from April 15 to July 15. He also announced three new emergency assistance programs that allowed small businesses to access more than $90 million in aid. On April 23, 2020, Pritzker extended the stay-at-home order through May 29 with some modifications. Churches were prohibited from holding meetings that had more than 10 people in attendance. Some churches defied Pritzker, held meetings, and filed federal lawsuits. On May 1, 2020, Pritzker enacted a statewide mask mandate. On May 5, 2020, Pritzker announced his reopening plan, "Restore Illinois". The plan had five phases and split the state's 11 existing Emergency Medical Services Regions into four reopening regions. The regions could reopen independently of one another. All regions were then in Phase Two, which allowed retail curbside pickup and delivery along with outdoor activities such as golf, boating, and fishing. Phase Three would allow manufacturing, offices, retail, barbershops, and salons to reopen with capacity limits, along with gatherings of fewer than 10 people. In Phase 4, gatherings of up to 50 people were allowed, restaurants and bars could reopen, travel resumed, and child care and schools reopened under guidance from the IDPH. In Phase 5, the economy fully reopened.
Sources: en.wikipedia.org
=== Mortality === Published studies on the survival of Sjögren's disease patients have been limited in various respects, perhaps owing to the relatively small sample sizes and the fact that secondary Sjögren's disease is associated with other autoimmune diseases. A 2010 study found a slight increase in mortality rates of Sjögren's patients compared with the remainder of the population. A 2016 study found that primary Sjögren's was not associated with an increase in all-cause mortality as compared with the general population, but that a subset of patients with extraglandular involvement, vasculitis, hypocomplementaemia, and cryoglobulinaemia may be at increased risk of mortality. A 2021 metaanalysis showed a 46% increase in mortality, with significantly greater mortality risk in patients with older age, male gender, vasculitis, interstitial lung disease, low complements, positive anti-La/SSB and cryoglobulinaemia. Among those without other autoimmune disorders, life expectancy is unchanged.
CREST is not easily diagnosed as it closely mimics symptoms of other connective tissue and autoimmune diseases. Diagnoses are usually given when a patient presents two or more of the five major clinical symptoms. Additionally, blood can be tested for positive ANA and ACA, and skin biopsies can be taken to help confirm a diagnosis.
By convention, the products form the numerator. However, the law of mass action is valid only for concerted one-step reactions that proceed through a single transition state and is not valid in general because rate equations do not, in general, follow the stoichiometry of the reaction as Guldberg and Waage had proposed (see, for example, nucleophilic aliphatic substitution by SN1 or reaction of hydrogen and bromine to form hydrogen bromide). Equality of forward and backward reaction rates, however, is a necessary condition for chemical equilibrium, though it is not sufficient to explain why equilibrium occurs. Despite the limitations of this derivation, the equilibrium constant for a reaction is indeed a constant, independent of the activities of the various species involved, though it does depend on temperature as observed by the van 't Hoff equation. Adding a catalyst will affect both the forward reaction and the reverse reaction in the same way and will not have an effect on the equilibrium constant. The catalyst will speed up both reactions thereby increasing the speed at which equilibrium is reached. Although the macroscopic equilibrium concentrations are constant in time, reactions do occur at the molecular level. For example, in the case of acetic acid dissolved in water and forming acetate and hydronium ions,
==== Chemistry ==== In organic chemistry, in situ refers to processes that take place within the reaction mixture without isolating intermediates. In one-pot synthetic sequences, for example, in situ work-up modifications allow multiple reaction steps to proceed within a single vessel, reducing personnel exposure to unstable or hazardous substances (such as azide intermediates), which may pose safety risks if isolated. Another example is the Corey–Chaykovsky reagent, a sulfur ylide generated in situ by deprotonating sulfonium halides with a strong base. This approach is used because unstabilized sulfur ylides are highly reactive; if isolated, they may decompose or lose reactivity. Consequently, their direct generation and use within the reaction mixture is more practical. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, Raman spectroscopy, and mass spectrometry facilitate real-time monitoring of in situ reactions. These methods detect short-lived substances that form during a reaction, such as intermediates that might not be stable enough to isolate, and adjust conditions to improve the process; all without disturbing the reaction itself. In electrochemistry, in situ experiments are performed under the normal operating conditions of an electrochemical cell, with the electrode maintained at a controlled potential (typically by a potentiostat). By contrast, ex situ experiments occur outside those operating conditions, usually without potential control; for example, after the electrode has been removed from the cell or left at open-circuit.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.